Chat with MASLD AI
Hi, I am MASLD AI.
Suggested Questions :
MASLD AI 09:44 AM
November 2025
In this session, Jeremy Davis, ACNP from Shreveport, Louisiana, breaks down a practical, step-by-step approach to evaluating abnormal liver chemistries. Using a real patient case, he reviews how to interpret ALT, AST, ALP, bilirubin, MCV, and GGT patterns; when to suspect hepatocellular, cholestatic, or mixed injury; and how to build an efficient differential using history, medications, alcohol assessment, and key labs (viral hepatitis panel, autoimmune markers, iron studies, Wilson disease testing, alpha-1 antitrypsin phenotype). He also highlights the role of ultrasound, MRCP, non-invasive fibrosis tests (FIB-4, ELF, VCTE), and when biopsy is needed. A practical, clinic-ready guide for APPs and clinicians assessing elevated liver enzymes and differentiating MASLD, alcohol-related disease, DILI, and other common etiologies.
Related Webcast
Webcast: MASLD Pharmacotherapy With Milly Ng
September 2025
Pharmacotherapy for MASLD is rapidly evolving, and clinicians now have more tools than ever to guide treatment decisions. In this session, Milly Ng, NP at Tufts Medical Center in Boston, breaks down a practical framework for when to initiate treatment, how to select the right therapy, and what monitoring strategies to use. From lifestyle modification and statins to GLP-1 receptor agonists and the first FDA-approved liver-directed therapy, resmetirom, this discussion highlights both established and emerging options. You’ll also learn how GLP-1s can support weight loss and liver health, the evidence behind vitamin E and pioglitazone, and the pivotal Maestro NASH trial that secured accelerated approval for resmetirom. Whether you’re managing patients with obesity, diabetes, or advanced fibrosis, this overview offers actionable strategies to simplify complex decisions and improve outcomes in MASLD/MASH care.
Watch Now
Webcast: MASLD Pharmacotherapy With Jill Olmstead
September 2025
Join Jill Olmstead, DNP from Providence Health for a practical, clinician-focused overview of MASLD pharmacotherapy and new treatment horizons for hepatic steatosis. This session in the GHAPP MASLD & MASH Community Network covers the shift in nomenclature, why care must be multidisciplinary (obesity, type 2 diabetes, dyslipidemia, hypertension, cardiovascular risk), and how to stage disease with FIB-4, noninvasive tests, and FibroScan before initiating therapy. Jill reviews lifestyle and weight-loss strategies, GLP-1 receptor agonists—their mechanisms, common GI side effects, and peri-procedure considerations due to delayed gastric emptying—plus where vitamin E and pioglitazone do and don’t fit today. She also walks through practical use of resmetirom for non-cirrhotic MASH with F2–F3 fibrosis (labs to order, monitoring, drug–drug interactions, and setting expectations alongside diet and exercise). If you’re a GI/hepatology clinician, APP, or primary-care partner looking to streamline risk reduction, staging, and evidence-based therapy for MASLD/MASH, this talk delivers step-by-step guidance you can use in clinic today.
Watch Now
Webcast: MASLD vs MetALD With Erin Tanner
November 2025
Join Erin Tanner, PA-C for a practical overview of MASLD (metabolic-associated steatotic liver disease) and MetALD, the overlap between metabolic dysfunction and alcohol-related liver injury. Through a real-world case, Erin explains how to interpret FibroScan (kPa/CAP) results, use PEth testing to objectively measure alcohol intake, and recognize how alcohol accelerates fibrosis progression. She reviews risk factors like hypertension, hyperlipidemia, and elevated triglycerides, emphasizing lifestyle interventions, Mediterranean diet, weight loss, and alcohol abstinence to prevent decompensation and liver cancer.
Watch Now
Webcast: Comparing F3 and F4 Fibrosis With Allysa Saggese
September 2025
In this session from the MASLD/MASH Community Network, Allysa Saggese, NP from Weill Cornell Medicine in New York, explores the critical differences between F3 and F4 fibrosis through two detailed case studies. Accurate staging is essential in fatty liver disease management, as it directly impacts treatment decisions, eligibility for FDA-approved therapies like resmetirom, and the need for hepatocellular carcinoma (HCC) surveillance. Allysa explains how non-invasive tests such as FIB-4, FibroScan, ELF, CAP, and MRI elastography compare, when to consider a liver biopsy, and how to interpret discordant results. She also discusses treatment pathways, the role of GLP-1 receptor agonists, lifestyle modification, and monitoring strategies for patients with advanced fibrosis versus cirrhosis. This practical overview provides clinicians with a clear framework to distinguish between F3 and F4, ensuring patients receive timely interventions, surveillance, and education to improve long-term outcomes in MASLD/MASH.
Watch Now
Webcast: MASLD Basics With Gabriella McCarty
August 2025
In this educational session, Gabriella McCarty, NP-C at Oshi Health, shares practical insights into Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MASH. Drawing from over 25 years of experience in GI, IBD, and hepatology, she explains how many fatty liver patients are discovered incidentally during workups for unrelated issues such as GERD or routine colonoscopy. Gabriella reviews the new global terminology (MASLD replacing NAFLD, MASH replacing NASH), outlines key metabolic risk factors that define MASLD, and walks through the role of non-invasive tests (FIB-4, FibroScan, ELF, ultrasound) in staging fibrosis. She emphasizes the importance of early detection, patient education, and primary care involvement in identifying at-risk individuals before progression to advanced fibrosis, cirrhosis, or liver cancer. This presentation highlights how MASLD can silently progress, why primary care and GI collaboration are critical, and the growing need for global awareness and prevention of progressive liver disease.
Watch Now
Webcast: MASLD vs MetALD Webcast
October 2025
In this educational presentation, Emily Przybyl, PA-C, from Erie County Medical Center, explores the overlap between Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MetALD, emphasizing how metabolic risk factors and alcohol intake accelerate liver injury and fibrosis. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this session uses a real-world case study to illustrate diagnostic evaluation, non-invasive testing (FibroScan, CAP score, FIB-4), and the role of PEth testing in objectively assessing alcohol use. Emily also highlights the importance of dietary changes, Mediterranean-style nutrition, weight reduction, and alcohol abstinence in preventing progression to cirrhosis and improving patient outcomes.
Watch Now
Webcast: MASLD vs MetALD With Scott Springer
October 2025
In this educational session, Scott Springer, PA-C, from Erie County Medical Center, discusses the intersection of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) and MetALD—a condition involving both metabolic dysfunction and alcohol-related liver injury. Presented through the GHAPP MASLD Community Network and supported by Madrigal Pharmaceuticals, this talk highlights diagnostic challenges, alcohol-use quantification, and the importance of objective biomarkers like PEth testing for accurate classification. Using a real patient case, Scott explains how metabolic risk factors and alcohol intake synergistically accelerate fibrosis, and how clinicians can apply non-invasive tests (FibroScan, ELF, FIB-4) and counseling strategies to improve patient outcomes.
Watch Now
Webcast: Lifestyle Management With Erin Parkinson
July 2025
In this impactful session from the GHAPP MASLD Community Network, Erin Parkinson, APRN, explores the vital role of lifestyle modifications in the management of MASLD (Metabolic dysfunction-associated steatotic liver disease) and MASH (Metabolic dysfunction-associated steatohepatitis). Through the lens of a real-world case study, Erin illustrates how clinical tools like FIB-4 and FibroScan® can be used to assess fibrosis risk and guide interventions for patients presenting with metabolic syndrome and hepatic steatosis. With a focus on practical, personalized care, this presentation highlights how diet, exercise, and culturally sensitive counseling can meaningfully reduce hepatic fat, inflammation, and fibrosis—key factors in preventing progression to cirrhosis or hepatocellular carcinoma. Erin discusses the impact of processed foods, high-fructose corn syrup, and sedentary behavior, while offering actionable guidance on introducing Mediterranean diets, intermittent fasting, and realistic exercise goals tailored to individual readiness and barriers. Whether you're a hepatology specialist, primary care provider, or obesity medicine clinician, this talk delivers tools to better support patients with MASLD/MASH through sustainable behavioral change and longitudinal follow-up.
Watch Now
Webcast: Lifestyle Management With Milly Ng
August 2025
Join Milly Ng, a hepatology nurse practitioner at Tufts Medical Center in Boston, for an evidence-based session on lifestyle management for MASLD and MASH, presented through the GHAPP MASLD Community Network and sponsored by Madrigal Pharmaceuticals. Through the case of "Albert," a patient with steatosis and metabolic risk factors, Milly highlights the importance of personalized counseling and non-invasive testing like FIB-4 and FibroScan to assess fibrosis risk. She reviews how Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its progressive form, MASH, can be reversed through diet, exercise, and weight loss, particularly before fibrosis advances to cirrhosis. Learn how to tailor dietary guidance to a patient's cultural background, socioeconomic status, and personal goals, and understand how central obesity and insulin resistance drive disease progression. Milly also reviews the genetic and environmental factors influencing steatosis, why aerobic training may be more effective than resistance workouts for liver health, and how validated tools like the EDAS (Exercise and Diet Adherence Scale) can track patient progress. This session empowers primary care and hepatology providers to deliver patient-centered lifestyle interventions that can prevent liver disease progression and reduce cardiometabolic risk.
Watch Now
Webcast: MASLD Pharmacotherapy With Cheryl Walsh
October 2025
In this talk, Cheryl Walsh, ACNP-C, reviews modern pharmacotherapy for MASLD/MASH—from foundational lifestyle/weight-loss strategies and GLP-1 receptor agonists to legacy options (vitamin E, pioglitazone) and the FDA-approved resmetirom with practical tips on dosing, monitoring, and drug–drug interactions (e.g., statins, procedure planning). She explains how to triage candidates, set realistic diet/exercise goals, and tailor guidance culturally, while outlining safety considerations (GI adverse effects, anesthesia risk) and follow-up with non-invasive tests. Presented via the GHAPP MASLD Community Network with support from Madrigal Pharmaceuticals, this session equips APPs to slow fibrosis progression and improve outcomes.
Watch Now